Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-33892
Titel: Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM)
VerfasserIn: Hoevelmann, J.
Muller, E.
Azibani, F.
Kraus, S.
Cirota, J.
Briton, O.
Ntsekhe, M.
Ntusi, N. A. B.
Sliwa, K.
Viljoen, C. A.
Sprache: Englisch
Titel: Clinical Research in Cardiology
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2021
Freie Schlagwörter: Peripartum cardiomyopathy
Heart failure
NT-proBNP
Left ventricular recovery
Risk stratification
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Introduction Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure worldwide. Although a significant number of women recover their left ventricular (LV) function within 12 months, some remain with persistently reduced systolic function. Methods Knowledge gaps exist on predictors of myocardial recovery in PPCM. N-terminal pro-brain natriuretic peptide (NT-proBNP) is the only clinically established biomarker with diagnostic value in PPCM. We aimed to establish whether NT-proBNP could serve as a predictor of LV recovery in PPCM, as measured by LV end-diastolic volume (LVEDD) and LV ejection fraction (LVEF). Results This study of 35 women with PPCM (mean age 30.0 ± 5.9 years) had a median NT-proBNP of 834.7 pg/ml (IQR 571.2–1840.5) at baseline. Within the first year of follow-up, 51.4% of the cohort recovered their LV dimensions (LVEDD < 55 mm) and systolic function (LVEF > 50%). Women without LV recovery presented with higher NT-proBNP at baseline. Multivariable regression analyses demonstrated that NT-proBNP of ≥ 900 pg/ml at the time of diagnosis was predictive of failure to recover LVEDD (OR 0.22, 95% CI 0.05–0.95, P = 0.043) or LVEF (OR 0.20 [95% CI 0.04–0.89], p = 0.035) at follow-up. Conclusions We have demonstrated that NT-proBNP has a prognostic value in predicting LV recovery of patients with PPCM. Patients with NT-proBNP of ≥ 900 pg/ml were less likely to show any improvement in LVEF or LVEDD. Our findings have implications for clinical practice as patients with higher NT-proBNP might require more aggressive therapy and more intensive follow-up. Point-of-care NT-proBNP for diagnosis and risk stratification warrants further investigation.
DOI der Erstveröffentlichung: 10.1007/s00392-021-01808-z
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-338928
hdl:20.500.11880/31204
http://dx.doi.org/10.22028/D291-33892
ISSN: 1861-0692
1861-0684
Datum des Eintrags: 21-Apr-2021
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Keiner Professur zugeordnet
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
Hoevelmann2021_Article_PrognosticValueOfNT-proBNPForM.pdf611,76 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons